Literature DB >> 9742920

Overestimation of hereditary breast cancer risk.

J D Iglehart1, A Miron, B K Rimer, E P Winer, D Berry, M J Shildkraut.   

Abstract

OBJECTIVE: To find out how women with breast or ovarian cancer rate their chances of carrying hereditary factors for these cancers and to determine the extent to which they overestimate their risk. SUMMARY BACKGROUND DATA: BRCA1 and BRCA2 are genes that cause breast and ovarian cancer when they are inherited in families. Testing for disease-associated mutations in these genes is now available commercially. Previous studies have shown that women overestimate their chances of carrying mutations. However, women's perceptions of risk have not been compared to objective estimates or to actual BRCA1 and BRCA2 testing results.
METHODS: This study examines estimates of carrying BRCA1 and BRCA2 mutations among women participating in a randomized trial comparing alternative precounseling educational materials. Estimates were provided by participants in a baseline mailed survey. Estimates given by participants were compared to those given by an expert panel and by a statistical model. Testing was offered free of charge and was done in an academic laboratory using standard techniques. Baseline estimates of participating women were compared to the estimates of the expert panel, to the carrier probability provided by the statistical model, and to actual testing results.
RESULTS: Women who have a personal history of breast or ovarian cancer significantly overestimate their risk of carrying hereditary factors for breast and ovarian cancer. Self-estimates exceeded the estimates of experts and a statistical model. One hundred women completed testing, and 21 mutations in BRCA1 or BRCA2 were found. Many test-negative women also overestimated their hereditary risk. Some women with a high carrier probability were negative for BRCA1 and BRCA2 mutations.
CONCLUSIONS: Overestimation of hereditary factors is common among affected women with a family history of cancer. Pretest education and counseling should reduce these high-risk perceptions. Better estimates of carrier probability will direct more intensive clinical services and research.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9742920      PMCID: PMC1191495          DOI: 10.1097/00000658-199809000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  Familial breast-ovarian cancer locus on chromosome 17q12-q23.

Authors:  S A Narod; J Feunteun; H T Lynch; P Watson; T Conway; J Lynch; G M Lenoir
Journal:  Lancet       Date:  1991-07-13       Impact factor: 79.321

2.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

3.  BRCA1--lots of mutations, lots of dilemmas.

Authors:  F S Collins
Journal:  N Engl J Med       Date:  1996-01-18       Impact factor: 91.245

4.  Physicians' knowledge of genetics and genetic tests.

Authors:  K J Hofman; E S Tambor; G A Chase; G Geller; R R Faden; N A Holtzman
Journal:  Acad Med       Date:  1993-08       Impact factor: 6.893

5.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Authors:  R Wooster; S L Neuhausen; J Mangion; Y Quirk; D Ford; N Collins; K Nguyen; S Seal; T Tran; D Averill
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

6.  Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior.

Authors:  C Lerman; K Kash; M Stefanek
Journal:  J Natl Cancer Inst Monogr       Date:  1994

7.  Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families.

Authors:  C M Phelan; J M Lancaster; P Tonin; C Gumbs; C Cochran; R Carter; P Ghadirian; C Perret; R Moslehi; F Dion; M C Faucher; K Dole; S Karimi; W Foulkes; H Lounis; E Warner; P Goss; D Anderson; C Larsson; S A Narod; P A Futreal
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

8.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

9.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.

Authors:  B B Roa; A A Boyd; K Volcik; C S Richards
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

10.  Interest in genetic testing among first-degree relatives of breast cancer patients.

Authors:  C Lerman; J Seay; A Balshem; J Audrain
Journal:  Am J Med Genet       Date:  1995-07-03
View more
  3 in total

1.  Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent.

Authors:  Kimberly Kelly; Howard Leventhal; Deborah Toppmeyer; Judy Much; James Dermody; Monica Marvin; Jill Baran; Marvin Schwalb
Journal:  J Genet Couns       Date:  2003-08       Impact factor: 2.537

2.  Testing for hereditary breast and ovarian cancer in the southeastern United States.

Authors:  A Miron; J M Schildkraut; B K Rimer; E P Winer; C Sugg Skinner; P A Futreal; D Culler; B Calingaert; S Clark; P Kelly Marcom; J D Iglehart
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

3.  Successful use of peer educators for sharing genetic information.

Authors:  Vickie L Venne; Heidi A Hamann
Journal:  J Genet Couns       Date:  2007-06-28       Impact factor: 2.537

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.